The updated CDC advice follows a unanimous vote from its Advisory Committee on Immunization Practices (ACIP) which involved ‘a robust discussion of the latest evidence on vaccine effectiveness, vaccine safety and rare adverse events, and consideration of the US vaccine supply’.
The recommendation from ACIP comes after the body was shown new data on the incidence of the blood-clotting condition, thrombocytopenia syndrome (TTS).
In the US, covering the period to the end of August 2021, 54 cases of TTS were identified following the J&J vaccine, while in data extending to December, 9 deaths have now been reported in the US. The highest rates of the condition were seen among women in their 30s and 40s.
